HUMIRA® for HCPs
SkyRizi™ for HCPs
RINVOQ™ for HCPs

NOW APPROVED For moderate to severe rheumatoid arthritis (RA) in adult MTX-IR patients1

Older woman in a harnass, ziplining Older woman in a harnass, ziplining Older woman in a harnass, ziplining
Power to help stop further joint damage with or without MTX Power to help stop further joint damage with or without MTX Power to help stop further joint damage with or without MTX

Achieved ranked secondary endpoint of mean change from baseline radiographic progression (ΔmTSS) at Week 26 or 241

RINVOQ is not indicated for MTX-naïve patients


IR=intolerance or inadequate response; MTX=methotrexate; mTSS=modified total sharp score

Clinical Trial Overview

*P ≤ 0.001 RINVOQ vs Placebo

SELECT-COMPARE (Study RA-IV) Study Design Intro2:
48-week, randomized, double-blind, active
comparator-controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX. The primary endpoint was ACR20 response at week 12 vs. placebo. Prespecified blinded rescue protocol occurred at weeks 14, 18, 22, or 26.

*P ≤ 0.001 RINVOQ vs MTX

RINVOQ is not indicated for MTX-naïve patients

SELECT-EARLY (Study RA-I) Study Design Intro4:
48-week, randomized, double-blind, active comparator-controlled study of 947 adult patients with moderate to severe RA who were MTX-naïve. The primary endpoint was ACR50 response at week 12. At week 26, non-responding patients were rescued according to prespecified criteria. 

Radiographic inhibition even without MTX Radiographic inhibition even without MTX Radiographic inhibition even without MTX

SELECT-COMPARE:
Radiographic Response
(Week 26)

RINVOQ + MTX vs Placebo + MTX

Results are based on random coefficient model.a Data observed after rescue are not included in the analysis.

SELECT-COMPARE was not designed to evaluate comparative effectiveness of radiographic outcomes vs. HUMIRA + MTX. This presentation cannot be interpreted as evidence of superiority, non-inferiority, or similarity of HUMIRA + MTX to RINVOQ + MTX or placebo + MTX.

Please see HUMIRA full Prescribing Information.

SELECT-EARLY:
Radiographic Response
(Week 24)

RINVOQ vs MTX

RINVOQ is not indicated for MTX-naïve patients

Please see HUMIRA full Prescribing Information.

Radiographic inhibition at Week 486-8

SELECT-COMPARE:
Radiographic Response
(Week 48)

RINVOQ + MTX

Results are based on random coefficient model.a Data observed after rescue are not included in the analysis (including placebo patients switched to RINVOQ at week 26).

SELECT-COMPARE was not designed to evaluate comparative effectiveness of radiographic outcomes vs. HUMIRA + MTX. This presentation cannot be interpreted as evidence of superiority, non-inferiority, or similarity of HUMIRA + MTX to RINVOQ + MTX.

Please see HUMIRA full Prescribing Information.

SELECT-EARLY:
Radiographic Response
(Week 48)

RINVOQ + MTX

RINVOQ is not indicated for MTX-naïve patients

Please see HUMIRA full Prescribing Information.

The SELECT-EARLY study: UPADAC without MTX

 

Dr. Stephen Hall describes a phase 3 trial evaluating UPADAC vs MTX in MTX-naive patients.*

*Note: UPADAC is not indicated for MTX-naïve patients.

Review the well-studied safety profile of RINVOQ

Find an overview of short- and long-term analyses.

Discover how ABBVIE is committed to providing exceptional access and patient support

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking